Market Cap : 321.32 M | Enterprise Value : 36.96 M | PE Ratio : At Loss | PB Ratio : 1.43 |
---|
NAS:ATRA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:ATRA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Atara Biotherapeutics's current ratio for the quarter that ended in Mar. 2022 was 3.10.
Atara Biotherapeutics has a current ratio of 3.10. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Atara Biotherapeutics's Current Ratio or its related term are showing as below:
During the past 10 years, Atara Biotherapeutics's highest Current Ratio was 52.75. The lowest was 3.10. And the median was 13.81.
ATRA's Current Ratio is ranked worse thanThe historical data trend for Atara Biotherapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Atara Biotherapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Atara Biotherapeutics's Current Ratio falls into.
The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.
Atara Biotherapeutics's Current Ratio for the fiscal year that ended in Dec. 2021
Atara Biotherapeutics's Current Ratio for the quarter that ended in Mar. 2022 is calculated as * For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
Current Ratio (A: Dec. 2021 ) = Total Current Assets (A: Dec. 2021 ) / Total Current Liabilities (A: Dec. 2021 )
= 384.621 / 105.786
= 3.64
Current Ratio (Q: Mar. 2022 ) = Total Current Assets (Q: Mar. 2022 ) / Total Current Liabilities (Q: Mar. 2022 )
= 314.389 / 101.562
= 3.10
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Thank you for viewing the detailed overview of Atara Biotherapeutics's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Yarema Kristin | officer: Chief Commercial Officer | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD., SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Murugan Amar | officer: SVP, GC & Secretary | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD,SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Dupont Jakob | officer: EVP, Head of R&D | C/O ONCOMED PHARMACEUTICALS, INC. 800 CHESAPEAKE DRIVE REDWOOD CITY CA 94063 |
Touchon Pascal | director, officer: President and CEO | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Koppikar Utpal | officer: Chief Financial Officer | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Mallik Ameet | director | C/O RAFAEL HOLDINGS, INC. 520 BROAD ST NEWARK NJ 07102 |
Renaud Ronald C Jr | director | C/O IDENIX PHARMACEUTICALS, INC. 60 HAMPSHIRE STREET CAMBRIDGE MA 02109 |
Seidenberg Beth C | director | |
Heiden William K | director | C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM MA 02451 |
Dobmeier Eric | director | C/O SAETTLE GENETICS INC 21823 30TH DRIVE SE BOTHELL WA 98021 |
Roncarolo Maria Grazia | director | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Gallagher Carol Giltner | director | C/O ATARA BIOTHERAPEUTICS, INC. 3260 BAYSHORE BOULEVARD BRISBANE CA 94005 |
Fust Matthew K | director | C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949 |
Baynes Roy D. | director | C/O RETROPHIN, INC. 12255 EL CAMINO REAL, SUITE 250 SAN DIEGO CA 92130 |
Berger Dietmar | officer: Global Head of R&D | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
Other Sources
By Zacks 2021-11-10
By Zacks 2022-02-24
By Zacks 2021-11-04
By Zacks 2021-01-26
By tipranks.com 2022-03-18
By Seekingalpha 2021-12-13